560 related articles for article (PubMed ID: 28843359)
81. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
82. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
83. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
Singh A; Mishra A
J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
[TBL] [Abstract][Full Text] [Related]
84. The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.
Del Re M; Rofi E; Cappelli C; Puppo G; Crucitta S; Valeggi S; Chella A; Danesi R; Petrini I
BMC Cancer; 2019 Apr; 19(1):410. PubMed ID: 31039766
[TBL] [Abstract][Full Text] [Related]
85. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
Li W; Qiu T; Guo L; Ling Y; Gao Y; Ying J; He J
Cancer Lett; 2018 Jun; 423():9-15. PubMed ID: 29524556
[TBL] [Abstract][Full Text] [Related]
86. Modification of osimertinib to discover new potent EGFR
Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
[TBL] [Abstract][Full Text] [Related]
87. Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.
DE Carlo E; Schiappacassi M; Pelizzari G; Baresic T; Del Conte A; Stanzione B; DA Ros V; Doliana R; Baldassarre G; Bearz A
In Vivo; 2021; 35(5):2941-2945. PubMed ID: 34410991
[TBL] [Abstract][Full Text] [Related]
88. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
89. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
[TBL] [Abstract][Full Text] [Related]
90. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
91. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
Buder A; Hochmair MJ; Schwab S; Bundalo T; Schenk P; Errhalt P; Mikes RE; Absenger G; Patocka K; Baumgartner B; Setinek U; Burghuber OC; Prosch H; Pirker R; Filipits M
J Thorac Oncol; 2018 Jun; 13(6):821-830. PubMed ID: 29505901
[TBL] [Abstract][Full Text] [Related]
92. BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC).
Patel HM; Shaikh M; Ahmad I; Lokwani D; Surana SJ
J Biomol Struct Dyn; 2021 May; 39(8):2838-2856. PubMed ID: 32276580
[TBL] [Abstract][Full Text] [Related]
93. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
94.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
95. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
96. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
97. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
Carlisle JW; Ramalingam SS
Future Oncol; 2019 Mar; 15(8):805-816. PubMed ID: 30657347
[TBL] [Abstract][Full Text] [Related]
98. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.
Mariachiara M; Celeste R; Federico F; Nicole B; Antonio C
Int Ophthalmol; 2018 Dec; 38(6):2669-2675. PubMed ID: 29071523
[TBL] [Abstract][Full Text] [Related]
99. Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in
Facchinetti F; Bozzetti F; Minari R; Ceccon G; Zielli T; Florindo I; Crisi G; Tiseo M
Tumori; 2018 Dec; 104(6):NP29-NP33. PubMed ID: 30392443
[TBL] [Abstract][Full Text] [Related]
100. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
